Peter J. Weiden

2 months ago | psychiatrictimes.com | Peter J. Weiden |Heidi Anne Duerr

In an exclusive interview with Psychiatric Times, Peter J.

Nov 30, 2024 | psychiatrictimes.com | Peter J. Weiden |Heidi Anne Duerr

(This is the second part of a video interview on the recent US Food and Drug Administration’s joint advisory committees vote to dismiss the clozapine REMS protocols. The first video discussed what the dismissal may mean for clinical care.)Peter J.

Nov 27, 2024 | psychiatrictimes.com | Peter J. Weiden |Heidi Anne Duerr

Peter J. Weiden, MD, clinical professor of psychiatry at the Renaissance School of Medicine at Stony Brook University in New York, provided critical insights into the challenges posed by the clozapine REMS (Risk Evaluation and Mitigation Strategies) program. His remarks followed a significant FDA joint advisory committee meeting that overwhelmingly recommended the dismantling of the current REMS framework for clozapine.

Jul 2, 2024 | psychiatrictimes.com | Peter J. Weiden

CLINICAL REFLECTIONSI began my career when the major treatments for schizophrenia were haloperidol and chlorpromazine. Since then, treatments for schizophrenia have improved slowly and incrementally, especially when looking back in the rearview mirror of what treatment used to be like.

May 8, 2024 | psychiatrictimes.com | Peter J. Weiden |John J. Miller

May 8, 2024Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation. CONFERENCE REPORTERPsychiatric Times Editor-in-Chief, John J. Miller, MD, sat down with his colleague, Peter J. Weiden, MD, of the State University of New York at Stony Brook at the 2024 American Psychiatric Association (APA) Annual Meeting.